Stock Quote
Alkermes, Inc. (ALKS.O) (Nasdaq)
$8.65
4:00pm EST
-0.12%
$8.66
$8.78
1,023,182
$8.90
$8.62
$13.16
$5.91
0.76
1,024,289
ALKS.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Pops, Richard | Chairman of the Board, President, Chief Executive Officer | 2,442,630 |
| Wall, Michael | Chairman Emeritus | -- |
| Frates, James | Chief Financial Officer, Senior Vice President, Treasurer | 1,211,530 |
Profile
Alkermes, Inc. (Alkermes) is an integrated biotechnology company. The Company has developed, manufactured and commercialized VIVITROL for alcohol dependence and manufactured RISPERDAL CONSTA for schizophrenia and bipolar disorder. Its pipeline includes injectable, pulmonary and oral products for the... Full Description
Company Address
Alkermes, Inc.
88 Sidney Street
Cambridge MA 02139
P: +1617.4940171
F: +1617.4949263
88 Sidney Street
Cambridge MA 02139
P: +1617.4940171
F: +1617.4949263
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Johnson & Johnson | $62.69 | +0.38 |
| Forest Laboratories, Inc. | $30.07 | +0.50 |
| Eli Lilly & Co. | $36.80 | +0.21 |
| ALKS.O | Industry | |
|---|---|---|
| P/E(TTM) | 10.38 | 12.80 |
| P/S(TTM) | 2.78 | 29.90 |
| ROI(TTM) | 15.57 | 2.35 |
| ROE(TTM) | 21.09 | 3.59 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -0.15 |
| EPS Est. (Current Year) | 1.38 |
| Total Revenue | $48.16M |
| Net Income | $-8.71M |
| EPS | $-0.09 |
